Nervous Disorder TRIZ Cases

Bezafibrate activates PPAR receptors to enhance mitochondrial biogenesis and reduce oxidative stress in neurodegenerative disease models.

Reducing MHC expression and overexpressing CD47 prevents microglial phagocytosis, enabling long-term cell survival in the central nervous system.

Affinity-matured antibodies target ASIC1a to resolve therapeutic reliability gaps in ischemic stroke treatment.

Fluorescent phospholipase A2 substrate detects enzymatic activity in cerebrospinal fluid to assess blood-neural barrier permeability.

Enucleated hematopoietic cells express specific antigens to induce immune tolerance.

A curcumin-boron complex oxygenates pathogenic amyloids through light irradiation.

Optimizing GGF2 dosing within a specific therapeutic window activates the PI3-kinase pathway while avoiding Mek1/Erk inhibition of Schwann cell myelination.

Protoxin-II variants with specific amino acid substitutions inhibit Nav1.7 activity to treat pain while avoiding non-selective channel blockade.

ACVR1 inhibitors block BMP signaling to overcome extrinsic inhibition of remyelination in chronic neuroinflammatory models.

Aromatic-cationic peptides inhibit cardiolipin peroxidation to resolve mitochondrial dysfunction in antiphospholipid syndrome treatment.

Hybrid AAV9 and AAVrh74 capsids swap variable regions to enhance muscle transduction while reducing liver toxicity.

Grafting murine CDRs onto human frameworks eliminates HAMA responses while preserving therapeutic efficacy against neurodegenerative disease targets.

Complement component 8-gamma protein modulates microglial activation to reduce neuroinflammatory cytokine production and behavioral impairments.

Engineered keratin BD-4 resolves extraction insolubility through modified amino acid sequences, enabling soluble protein production.

Cyclic nutrient restriction lowers amyloid plaques and tau proteins, addressing underlying pathology beyond symptom management.

Engineered antibodies target aggregated alpha-synuclein forms to enable specific detection of neurodegenerative disease markers.

Assaying adipogenic adenovirus infection resolves the evidence gap linking viral presence to obesity-related cancer aggressiveness.

Flupirtine derivatives upregulate Bcl-2 expression and activate autophagy, resolving low in vivo concentration challenges.

Isofagomine tartrate stabilizes glucocerebrosidase against aggregation, enabling reliable subcutaneous administration with improved serum exposure.

Oligodendrocyte precursor cells undergo enrichment using specific surface markers to resolve purity and complexity trade-offs.

SV2A inhibitors treat cognitive impairment by altering synaptic vesicle dynamics to slow decline.

Segmented biphasic dosing maintains anti-VLA-4 trough levels while reducing progressive multifocal leukoencephalopathy risk through extended interval scheduling.

Targeting KIF19 and CEP192 proteins blocks fibroblast migration, resolving the trade-off between effective wound closure and pathological tissue scarring.

Segmented linker backbones resolve construct complexity while maintaining high therapeutic index for targeted tumor therapy.

Form F variable hydrate structure stabilizes PDE10 inhibitor manufacturing by resolving polymorph identification complexity and shelf-life trade-offs.

A biodegradable nasal implant delivers therapeutic agents directly to the central nervous system via the olfactory pathway.

Engineered polypeptides incorporate an albumin binding domain to sequester the therapeutic compound in circulation and decrease renal clearance.

Anti-N3pGlu antibodies bind amyloid beta deposits to slow cognitive decline in patients.

Y-shaped branched polyethylene glycol derivatives modify interferon alpha-2a at a single amino acid residue.

Microbial transglutaminase links a glycine-based peptide to antibody glutamine residues for precise bioconjugation.

Optimized compounds inhibit MAPK phosphorylation, resolving inadequate tumor delivery and side effects from systemic chemotherapy.

Peptide agents inhibit PSD-95 binding to NMDA receptors, reducing anxiety without side effects.

Anti-PD-1 antibodies agonize PD-1 to reduce inflammation in immune disorders.

Combines azelastine and alprazolam to reduce adverse effects by inhibiting inflammatory mediators and stabilizing mast cells.

Screening platforms identify KCC2 expression enhancing compounds to restore excitatory-inhibitory neurotransmission balance in Rett syndrome.

Anti-idiotype antibodies target homologous B cell receptors to resolve non-curative treatment limitations in chronic lymphocytic leukemia.

Merged Class I Ec and Ea IGF-1 sequences in plasmid vectors resolve the trade-off between treatment simplicity and therapeutic effectiveness.

Continuous flow radical reactions replace expensive tetralone starting materials to lower costs while maintaining high yield and purity.

Engineered 6A3 antibodies bind Nogo-A with high specificity, extending half-life and reducing dosing frequency for CNS injury treatment.

Conformation-selective antibodies neutralize pathogenic ADDLs without triggering CNS inflammation, reversing memory loss.